

Attorney Docket No.: 5784.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Arne Staby


Application No.: TBA

Group Art Unit: TBA

Filed: September 27, 2000

Examiner: TBA

For: Ion exchange chromatography of proteins and peptides

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. **Copies of references were filed with USSN 09/522,694 filed March 10, 2000, the benefit of which is claimed under 35 USC 120.**

The references are as follows:

1. US 4,129,560
2. US 5,101,103
3. US 3,907,676
4. WO 90/00176


5. WO 90/00177
6. EP 0 207 727
7. EP 0 849 277
8. Dizdaroglu et al., Abstract, BIOSIS accession no. 198274065982
9. Stadalius et al., Abstract, BIOSIS accession no. 198783093472
10. Lamy et al., Archives of Biochemistry and Biophysics, Vol. 193, No. 1, pp. 140-149 (March 1979)
11. Brange et al., Acta Pharm. Nord., Vol. 4, No. 4, pp. 223-232 (1992)
12. Bjoern et al., Activation of Coagulation Factor VII to VIIa, Res. Discl. No. 26960, pp. 564-565 (September 1986)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: September 27, 2000



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123